Nefazodone hydrochloride, 5-HT2A antagonist

Be the first to review this product! Submit a review

|

(0 Publication)

MW 506.5 Da, Purity >99%. Potent 5-HT2A receptor antagonist (Ki = 7.1 nM for inhibition of [3H] ketanserin binding in rat cortex). Additionally blocks α1 adrenoceptors (Ki values are 5.5 and 84 nM at α1 and α2, respectively). Acts as a serotonin-norepinephrine-dopamine reuptake inhibitor (SNDRI) (Ki values are 220 and 555 nM at rat SERT and NET, respectively). Antidepressant.

View Alternative Names

2700049B16Rik, 3110031N04Rik, ACLS, AI838772, AIS, ANDR_HUMAN, AR, AR8, ARO, ARO1, AW493413, Androgen nuclear receptor variant 2, Androgen receptor, Androgen receptor (dihydrotestosterone receptor; testicular feminization; spinal and bulbar muscular atrophy; Kennedy disease), Aromatase, Atherosclerosis, susceptibility to, included, BK channel, BK channel beta subunit, BK channel subunit beta-1, BK channel subunit beta-2, BK channel subunit beta-4, BKCA alpha, BKCA alpha subunit, BKTM, BKbeta, BKbeta1, BKbeta2, BKbeta4, BXR, CAPC, CP19A_HUMAN, CPV1, CYAR, CYP19, CYPXIX, Calcium activated potassium channel beta 4 subunit, Calcium activated potassium channel subfamily M subunit beta 1, Calcium activated potassium channel subfamily M subunit beta 2, Calcium activated potassium channel subfamily M subunit beta 4, Calcium-activated potassium channel, Calcium-activated potassium channel subunit alpha-1, Calcium-activated potassium channel subunit beta, Calcium-activated potassium channel subunit beta-1, Calcium-activated potassium channel subunit beta-2, Calcium-activated potassium channel subunit beta-4, Charybdotoxin receptor subunit beta-1, Charybdotoxin receptor subunit beta-2, Charybdotoxin receptor subunit beta-4, Cyp19a1, Cytochrome P-450AROM, Cytochrome P450 19A1, Cytochrome P450, family 19, subfamily A, polypeptide 1, Cytochrome P450, subfamily XIX (aromatization of androgens), Cytokeratin-associated protein in cancer, DHTR, DKFZp686N23123, DNA binding protein, Dihydro testosterone receptor, Dihydrotestosterone receptor (DHTR), Drosophila slowpoke like, ER, ER-alpha, ER-beta, ERR a, ERR-alpha, ERR1 protein, ERR1_HUMAN, ER[a], ER[b], ESR, ESR B, ESR BETA, ESR1_HUMAN, ESRA, ESRL 1, ESRR A, ESTR B, Eag-related protein 1, Era, Erb, Erb2, Estr, Estra, Estradiol Receptor alpha, Estradiol Receptor beta, Estradiol receptor, Estrogen Receptor 1, Estrogen Receptor 2, Estrogen receptor, Estrogen receptor 1 (alpha), Estrogen receptor 2 (ER beta), Estrogen receptor 2 ER beta, Estrogen receptor alpha, Estrogen receptor beta 4, Estrogen receptor related 1, Estrogen receptor-like 1, Estrogen resistance, included, Estrogen synthase, Estrogen synthetase, Estrogen-related receptor alpha, Estrra, Ether a go go related potassium channel protein, Ether-a-go-go-related gene potassium channel 1, Ether-a-go-go-related protein 1, FLJ11090, GCCR, GCPS, GCRST, GCR_HUMAN, GLI Kruppel family member GLI 3, GLI Kruppel family member GLI3 (Greig cephalopolysyndactyly syndrome), GLI family zinc finger 3, GLI3 C-terminally truncated form, GLI3 form of 190 kDa, GLI3 form of 83 kDa, GLI3 full length protein, GLI3-190, GLI3-83, GLI3FL, GLI3_HUMAN, GR, Glioma associated oncogene family zinc finger 3, Glucocorticoid receptor, Grl1, H-ERG, HDL cholesterol, augmented response of, to hormone replacement, included, HUMARA, HYSP1, Hbeta1, Hbeta2, Hbeta3, Hbeta4, IMD42, K(VCA)alpha, K(VCA)beta, K(VCA)beta-1, K(VCA)beta-2, K(VCA)beta-4, KCMA1_HUMAN, KCMB1_HUMAN, KCMB2_HUMAN, KCMB4_HUMAN, KCNH2_HUMAN, KCNMA, KCNMA1, KCNMB 1, KCNMB 2, KCa1.1, KD, Kennedy disease (KD), Kv11.1, LQT 2, LRC26_HUMAN, Large conductance Ca2+ activated K+ channel beta 1 subunit, Large conductance Ca2+ activated K+ channel beta2 subunit, Large conductance calcium activated potassium channel beta 2 subunit, Large conductance calcium dependent potassium ion channel beta 4 subunit, Leucine-rich repeat-containing protein 26, Lrrc26, MGC104252, MGC104309, MGC112732, MGC129539, MGC22431, MGC57945, Maxi K channel, Maxi K channel beta subunit, Maxi K channel subunit beta-1, Maxi K channel subunit beta-2, Maxi K channel subunit beta-4, Maxi Potassium channel alpha, MaxiK, MaxiK channel beta 2 subunit, Microsomal monooxygenase, Myocardial infarction, susceptibility to, included, NF-E2-related factor 2, NF2L2_HUMAN, NR1F3, NR1I2_HUMAN, NR3A1, NR3A2, NR3B1, NR3C3, NR3C4, NRF2, Nfe2l2, Nuclear factor, Nuclear factor (erythroid derived 2) like 2, Nuclear factor erythroid 2-related factor 2, Nuclear factor erythroid derived 2 like 2, Nuclear receptor ROR-gamma, Nuclear receptor RZR-gamma, Nuclear receptor subfamily 1 group F member 3, Nuclear receptor subfamily 1 group I member 2, Nuclear receptor subfamily 3 group A member 1, Nuclear receptor subfamily 3 group A member 2, Nuclear receptor subfamily 3 group B member 1, Nuclear receptor subfamily 3 group C member 1, Nuclear receptor subfamily 3 group C member 3, Nuclear receptor subfamily 3 group C member 4, Nuclear receptor subfamily 3 group C member 4 (NR3C4), ONR 1, OTTHUMP00000017718, OTTHUMP00000017719, OTTHUMP00000162543, OTTHUMP00000198350, OTTHUMP00000215173, OTTHUMP00000215174, OTTHUMP00000215175, Oncogene GLI3, Orphan nuclear receptor PAR 1, Orphan nuclear receptor PXR, P 450AROM, PAP A, PAPB, PAR, PAR q, PGR, PPD IV, PR, PRA, PRB, PRGR_HUMAN, PRR, Potassium channel HERG, Potassium large conductance calcium activated channel subfamily M beta member 1, Potassium large conductance calcium activated channel subfamily M beta member 2, Potassium large conductance calcium activated channel subfamily M beta member 4, Potassium voltage gated channel subfamily H (eag related) member 2, Potassium voltage-gated channel subfamily H member 2, Pregnane X receptor, Progesterone receptor, Progestin receptor form A, Progestin receptor form B, RAR related orphan nuclear receptor variant 2, RAR related orphan receptor C, isoform a, RAR related orphan receptor gamma, RAR-related orphan receptor C, RNESTROR, RORG_HUMAN, RP24-311F12.2, RZR GAMMA, RZRG, Retinoic acid binding receptor gamma, Retinoid-related orphan receptor-gamma, Rorc, SAKCA, SBMA, SCAN1, SLO, SMAX1, SQT1, SXR, Slo homolog, Slo-alpha, Slo-beta, Slo-beta-1, Slo-beta-2, Slo-beta-4, Slo1, Slowpoke homolog, Spinal and bulbar muscular atrophy, Spinal and bulbar muscular atrophy (SBMA), Steroid and xenobiotic receptor, Steroid hormone receptor ERR1, TFM, TOR, TYDP, TYDP1_HUMAN, Testicular Feminization (TFM), Transcriptional activator GLI3, Transcriptional repressor GLI3R, Tyr-DNA phosphodiesterase 1, Tyrosyl-DNA phosphodiesterase 1, Voltage gated potassium channel, subfamily H, member 2, Voltage-gated potassium channel subunit Kv11.1, Zinc finger protein GLI 3, androgen receptor splice variant 4b, bA350O14.10, cytokeratin-associated protein, eag homolog, erythroid derived 2, estrogen receptor related receptor alpha, flavoprotein-linked monooxygenase, glucocorticoid nuclear receptor variant 1, hERG-1, hERR1, hSlo, hslo beta, like 2, nr3c1, nuclear factor erythroid 2 like 2, nuclear receptor subfamily 3, group C, member 1 (glucocorticoid receptor), pregnane X nuclear receptor variant 2, subfamily M subunit alpha-1, subfamily M subunit beta-1, subfamily M subunit beta-2, subfamily M subunit beta-4